Skip to main content
Top
Published in: Medical Oncology 6/2014

01-06-2014 | Original Paper

Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia

Authors: Nina Petrović, Vesna Mandušić, Bogomir Dimitrijević, Jelena Roganović, Silvana Lukić, Lidija Todorović, Boban Stanojević

Published in: Medical Oncology | Issue 6/2014

Login to get access

Abstract

MicroRNAs play essential role in breast carcinoma progression and invasion. Our principal goals were to assess clinicopathological and prognostic correlations of microRNA-21 (miR-21) expression levels in a group of 39 Serbian breast cancer patients with invasive lobular (ILC), ductal (IDC), or mixed (ILC–IDC) breast carcinomas and in order to discover the role of miR-21 in potential novel form of stratification of the patients with different estrogen receptor (ER) and progesterone receptor (PR) status. MiR-21 expression levels were measured by stem-loop real-time RT-PCR using TaqMan technology. ER, PR, human epidermal growth factor 2 receptor (Her-2), and proliferative index (Ki-67) were evaluated by immunohistochemistry. MiR-21 levels do not vary among ILC, IDC, and ILC–IDC subgroups. MiR-21 expression levels varied significantly in the age, tumor size, Ki-67, and different grade (p = 0.030, p = 0.036, p = 0.027 and p = 0.032, respectively) subgroups. ER+ and PR+ showed higher miR-21 levels than their negative receptor status paired groups ER− and PR− with p = 0.012 and p = 0.018, respectively. MiR-21 positively correlated with ER and PR status (p = 0.018, ρ = 0.379 and p = 0.034, ρ = 0.345, respectively). Our findings suggest that miR-21 emulates transitional form of expression and that the levels of expression might be useful for stratification of the patients with different receptor status with the purpose to seek for new therapy approaches especially for the patients with the lack of response to conventional endocrine therapy.
Literature
3.
go back to reference Huang G-L, Zhang X-H, Guo G-L, Huang K-T, Yang K-Y, Shen X, You J, Hu X-Q. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009. doi:10.3892/or_00000270. Huang G-L, Zhang X-H, Guo G-L, Huang K-T, Yang K-Y, Shen X, You J, Hu X-Q. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009. doi:10.​3892/​or_​00000270.
6.
go back to reference Qi L, Bart J, Tan L, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H, Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163. doi:10.1186/1471-2407-9-163.PubMedCentralPubMedCrossRef Qi L, Bart J, Tan L, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H, Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163. doi:10.​1186/​1471-2407-9-163.PubMedCentralPubMedCrossRef
7.
go back to reference Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49:1067–77. doi:10.1186/bcr1285.PubMedCrossRef Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49:1067–77. doi:10.​1186/​bcr1285.PubMedCrossRef
9.
go back to reference Span PN, Lindberg RLP, Manders P, Tjan-Heijnen VCG, Heuvel JJTM, Beex LVAM, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004;202(4):395–402. doi:10.1002/path.1528.PubMedCrossRef Span PN, Lindberg RLP, Manders P, Tjan-Heijnen VCG, Heuvel JJTM, Beex LVAM, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004;202(4):395–402. doi:10.​1002/​path.​1528.PubMedCrossRef
10.
go back to reference Mylona E, Magkou C, Giannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A, Nakopoulou L. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res. 2006;8(5):R57. doi:10.1186/bcr1607.PubMedCentralPubMedCrossRef Mylona E, Magkou C, Giannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A, Nakopoulou L. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res. 2006;8(5):R57. doi:10.​1186/​bcr1607.PubMedCentralPubMedCrossRef
11.
go back to reference Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, Ma Y, Li D. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Sur Oncol. 2013;2013:1–7. doi:10.1155/2013/875078.CrossRef Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, Ma Y, Li D. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Sur Oncol. 2013;2013:1–7. doi:10.​1155/​2013/​875078.CrossRef
13.
go back to reference Lopez-Camarillo C, Fonseca-Sánchez MA, Flores-Pérez A, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, et al. Functional roles of microRNAs in cancer: microRNomes and oncomiRs connection. In: Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, Perez Plasencia C, Fuentes-Mera L, et al., editors. Oncogenomics and cancer proteomics—novel approaches in biomarkers discovery and therapeutic targets in cancer. InTech, p. 72–89, 2013; 9(1):53–9. doi:10.1111/j.1743-7563.2012.01548.x. Lopez-Camarillo C, Fonseca-Sánchez MA, Flores-Pérez A, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, et al. Functional roles of microRNAs in cancer: microRNomes and oncomiRs connection. In: Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, Perez Plasencia C, Fuentes-Mera L, et al., editors. Oncogenomics and cancer proteomics—novel approaches in biomarkers discovery and therapeutic targets in cancer. InTech, p. 72–89, 2013; 9(1):53–9. doi:10.​1111/​j.​1743-7563.​2012.​01548.​x.
14.
16.
go back to reference Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199–208.PubMedCrossRef Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199–208.PubMedCrossRef
17.
go back to reference Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11(3):R27. doi:10.1186/bcr2257.PubMedCentralPubMedCrossRef Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11(3):R27. doi:10.​1186/​bcr2257.PubMedCentralPubMedCrossRef
18.
go back to reference Verkooijen HM, Fioretta Gr, Vlastos G, Morabia A, Schubert H, Sappino A-P, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int Cancer. 2003;104(6):778–81. doi:10.1002/ijc.11032.CrossRef Verkooijen HM, Fioretta Gr, Vlastos G, Morabia A, Schubert H, Sappino A-P, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int Cancer. 2003;104(6):778–81. doi:10.​1002/​ijc.​11032.CrossRef
19.
go back to reference Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. Med Oncol. 2014;31(3):867. doi:10.1007/s12032-014-0867-x.PubMedCrossRef Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. Med Oncol. 2014;31(3):867. doi:10.​1007/​s12032-014-0867-x.PubMedCrossRef
20.
go back to reference Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67(21):10582–91.PubMedCrossRef Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67(21):10582–91.PubMedCrossRef
21.
go back to reference Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7(5):R753. doi:10.1186/bcr1285.PubMedCentralPubMedCrossRef Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7(5):R753. doi:10.​1186/​bcr1285.PubMedCentralPubMedCrossRef
22.
25.
go back to reference Kim YJ, Hwang SJ, Bae YC, Jung JS. miR-21 regulates adipogenic differentiation through the modulation of TGF-β signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 2009;27(12):3093–102. doi:10.1002/stem.235.PubMed Kim YJ, Hwang SJ, Bae YC, Jung JS. miR-21 regulates adipogenic differentiation through the modulation of TGF-β signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 2009;27(12):3093–102. doi:10.​1002/​stem.​235.PubMed
26.
go back to reference Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2008;117(1):131–40. doi:10.1007/s10549-008-0219-7.PubMedCrossRef Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2008;117(1):131–40. doi:10.​1007/​s10549-008-0219-7.PubMedCrossRef
27.
28.
go back to reference Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70. doi:10.1158/0008-5472.CAN-05-1783.PubMedCrossRef Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70. doi:10.​1158/​0008-5472.​CAN-05-1783.PubMedCrossRef
30.
go back to reference Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5(1):24. doi:10.1186/1476-4598-5-24.PubMedCentralPubMedCrossRef Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5(1):24. doi:10.​1186/​1476-4598-5-24.PubMedCentralPubMedCrossRef
31.
go back to reference Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Nat Cancer Inst. 2005;97(17):1254–61. doi:10.1093/jnci/dji249.PubMedCrossRef Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Nat Cancer Inst. 2005;97(17):1254–61. doi:10.​1093/​jnci/​dji249.PubMedCrossRef
Metadata
Title
Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia
Authors
Nina Petrović
Vesna Mandušić
Bogomir Dimitrijević
Jelena Roganović
Silvana Lukić
Lidija Todorović
Boban Stanojević
Publication date
01-06-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 6/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0977-5

Other articles of this Issue 6/2014

Medical Oncology 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.